I love your subject line! [General Sta­tis­tics]

posted by Helmut Homepage – Vienna, Austria, 2019-08-08 12:31 (1914 d 19:41 ago) – Posting: # 20487
Views: 9,850

Ahoy, my Capt’n,

❝ ❝ The precise model [:blahblah:]


❝ But on the other hand: Why then then include e.g. period?


[image]Cause otherwise eventual period effects would not mean out. ;-)

Given, sometimes one has to assume lacking period effects and everybody is happy with that. If an originator explores whether the drug follows linear PK, we have a paired design (SD → saturation → steady state) and compare AUC0–τ with AUC0–∞. A crossover would be a logistic nightmare.

❝ Let us for a moment disregard the actual wording. [lengthy beautiful explanation]


Exactly.

❝ […] For a parallel trial I think I want group in the model. If regulators don't like this, they can ask me to take it away. I happily do so without protesting. I am a sheep at that point. But not until then. :-D


Agree again.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,280 posts in 4,889 threads, 1,655 registered users;
62 visitors (0 registered, 62 guests [including 7 identified bots]).
Forum time: 07:12 CET (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5